Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase (TLT) grants 7,860,000 stock options at $ 0.25

<< Previous

Bullboard Posts

Next >>

Comment by 99942Apophison Nov 28, 2022 1:59pm

325 Views

Post# 35134414

RE:RE:RE:RE:RE:RE:RE:RE:RE:Theralase (TLT) grants 7,860,000 stock options at $ 0.25

Thanks ScienceFirst, using your contributed figure of 178.83 PE ratio from that chart for Drug Biotechnology would imply a share price from net profit per share estimated @ $0.39 X 178.83 = $69.74 . Not too scruffy eh!

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant